Author Archives: Molly Blauvelt

New treatment approved for mild-to-moderate atopic dermatitis

A new cream for the treatment of patients with mild-to-moderate atopic dermatitis (also commonly called eczema) was recently approved by the FDA. The generic name of the medication is ruxolitinib, and the trade name is Opzelura®. Typical treatments for eczema patients are dominated by topical steroids, such as triamcinolone cream, which patients will often use […]


The Psoriasis Pipeline

Recently, Dr. Andy Blauvelt, President of Oregon Medical Research Center (OMRC), was interviewed by the American Academy of Dermatology regarding upcoming drugs that will likely become available soon to treat psoriasis. Dr. Blauvelt, an international expert in psoriasis, has experience using all of these medications while participating in clinical trials for these drugs at OMRC. […]



Clinical Trial Evaluating New Eczema Drug Shows Promising Results

Atopic dermatitis (AD), also known as eczema, is a common skin disease that significantly impacts quality of life. One of the most distressing symptoms of this disease is itching, which can often lead to disruption of the skin barrier and skin infection. OMRC recently participated in a 16-week study evaluating a new treatment for AD, […]


Relief for Genital Psoriasis

Yes, let’s talk “genital psoriasis,” even though many people don’t want to talk about it. Genital psoriasis, in both women and men, is hard to talk about, hard to treat, and has a big impact on intimate relationships as well as normal daily functioning. Up to 40% of psoriasis patients report lesions in the genital […]


Comparison study shows efficacy of new targets

Several recent clinical trials in patients with moderate‐to‐severe psoriasis have demonstrated that inhibitors targeting IL‐17 and IL‐23 can offer patients high levels of skin clearance. The IXORA‐R trial focuses on early responses to treatment. Because patients have indicated that rapid, complete clearance of psoriasis is a priority, the primary endpoint of IXORA‐R is complete clearance at […]